6月24日 - ** 药物研发公司Viking Therapeutics(VKTX.O)股价上涨5.7%,报36.78美元
** VKTX启动新药VK3019的I期临床试验,用于治疗代谢性疾病和肥胖症
** VK3019 靶向阿米林和降钙素受体,有助于抑制食欲、控制血糖并促进减重
** 该公司将于今年晚些时候启动III期临床试验,评估口服药物VK2735在治疗肥胖和超重方面的疗效
** 计入本交易日涨幅,该股年初至今累计上涨4.49%
6月24日 - ** 药物研发公司Viking Therapeutics(VKTX.O)股价上涨5.7%,报36.78美元
** VKTX启动新药VK3019的I期临床试验,用于治疗代谢性疾病和肥胖症
** VK3019 靶向阿米林和降钙素受体,有助于抑制食欲、控制血糖并促进减重
** 该公司将于今年晚些时候启动III期临床试验,评估口服药物VK2735在治疗肥胖和超重方面的疗效
** 计入本交易日涨幅,该股年初至今累计上涨4.49%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.